Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction

被引:3
作者
Levy, Liran [1 ,2 ]
Moshkelgosha, Sajad [1 ]
Huszti, Ella [3 ,4 ]
Hunter, Sarah [1 ]
Renaud-Picard, Benjamin [1 ]
Berra, Gregory [1 ]
Kawashima, Mitsuaki [1 ]
Fernandez-Castillo, Juan [1 ]
Fuchs, Eyal [1 ]
Dianti, Milagros [1 ]
Ghany, Rasheed [1 ]
Keshavjee, Shaf [1 ,4 ]
Singer, Lianne G. [1 ,4 ]
Tikkanen, Jussi [1 ]
Martinu, Tereza [1 ,4 ,5 ]
机构
[1] Univ Hlth Network, Toronto Lung Transplant Program, Toronto, ON, Canada
[2] Tel Aviv Univ, Inst Pulm Med, Sackler Fac Med, Sheba Med Ctr, Tel Aviv, Israel
[3] Univ Hlth Network, Biostat Res Unit, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Toronto Gen Hosp, 585 Univ Ave, PMB 11-128, Toronto, ON M5G 2N2, Canada
基金
加拿大健康研究院;
关键词
lung transplant; chronic lung allograft dysfunction phenotypes; restrictive allograft syndrome; mixed phenotype; bronchiolitis obliterans syndrome; epithelial cell death; BRONCHIOLITIS OBLITERANS SYNDROME; SURFACTANT PROTEIN-A; PROGNOSTIC VALUE; AIRWAY MUCUS; SERUM; KL-6; TRANSPLANTATION; CA-125; FLUID; TRANSITION;
D O I
10.1016/j.healun.2023.03.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Airway epithelial injury is thought to be a key event in the pathogenesis of chronic lung allograft dysfunction (CLAD). We investigated whether markers of epithelial activity and injury in bronchoalveolar lavage fluid (BAL) correlate with CLAD diagnosis and major CLAD phenotypes: bronchiolitis obliterans syndrome (BOS) vs restrictive allograft syndrome (RAS)-related phenotypes (including RAS, mixed phenotype, and all other patients with RAS-like opacities).METHODS: CLAD status and phenotypes were retrospectively determined in a cohort of all consecutive adult, first, bilateral lung transplants performed 2010-2015, with available BAL samples. All patients with RAS-related phenotypes were included and 1:1 matched with BOS patients based on the time from transplant to CLAD-onset. Subjects who were CLAD-free for a minimum of 3 years post -transplant were 1:1 matched to CLAD patients and included as controls. Proteins that maintain the barrier function of the airway epithelial mucosa (club cell secretory protein, surfactant protein-D and epithelial mucins: MUC1, MUC5AC, MUC5B, MUC16), as well as epithelial cell death markers (M30 & M65 representing epithelial cell apoptosis and overall death, respectively), were measured in BAL obtained within 6-months post CLAD onset using a double-sandwich ELISA or a multiplex bead assay. Protein levels were compared using Mann-Whitney-U-test. Association between protein levels and graft survival was assessed using Cox proportional hazards models, adjusted for CMV serology mismatch status and CLAD phenotype.RESULTS: Fifty-four CLAD (27 BOS, 11 RAS, 7 mixed, 9 others with RAS-like opacities) patients and 23 CLAD-free controls were included. Median BAL levels were significantly higher in patients with CLAD compared to CLAD-free controls for M30 (124.5 vs 88.7 U/L), MUC1 (6.8 vs 3.2 pg/mL), and MUC16 (121.0 vs 30.1 pg/mL). When comparing CLAD phenotypes, M30 was significantly higher in patients with RAS-related phenotypes than BOS (160.9 vs 114.6 U/L). In multivariable models, higher M30 and MUC5B levels were associated with decreased allograft survival after CLAD onset independent of phenotype (p < 0.05 for all).CONCLUSIONS: Airway epithelial mucins and cell death markers are enhanced in the BAL of patients with CLAD and can assist in differentiating between CLAD phenotypes and post-CLAD outcomes. Abnormal airway mucin expression and epithelial cell death may be involved in the pathogenesis of CLAD, and therefore their detection may aid in future selection of targeted therapies. J Heart Lung Transplant 2023;42:1152-1160 & COPY; 2023 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:1152 / 1160
页数:9
相关论文
共 43 条
  • [1] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA
    BAST, RC
    FEENEY, M
    LAZARUS, H
    NADLER, LM
    COLVIN, RB
    KNAPP, RC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) : 1331 - 1337
  • [2] The three R's of lung health and disease: repair, remodeling, and regeneration
    Beers, Michael F.
    Morrisey, Edward E.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) : 2065 - 2073
  • [3] Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation
    Borthwick, L. A.
    Parker, S. M.
    Brougham, K. A.
    Johnson, G. E.
    Gorowiec, M. R.
    Ward, C.
    Lordan, J. L.
    Corris, P. A.
    Kirby, J. A.
    Fisher, A. J.
    [J]. THORAX, 2009, 64 (09) : 770 - 777
  • [4] Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
    Bos, Saskia
    De Sadeleer, Laurens J.
    Vanstapel, Arno
    Beeckmans, Hanne
    Sacreas, Annelore
    Yserbyt, Jonas
    Wuyts, Wim A.
    Vos, Robin
    [J]. EUROPEAN RESPIRATORY REVIEW, 2021, 30 (160)
  • [5] Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Cedres, Susana
    Nunez, Isaac
    Longo, Marina
    Martinez, Pablo
    Checa, Eva
    Torrejon, Davis
    Felip, Enriqueta
    [J]. CLINICAL LUNG CANCER, 2011, 12 (03) : 172 - 179
  • [6] Prognostic value of surfactant proteins A and D in patients with acute lung injury
    Cheng, IW
    Ware, LB
    Greene, KE
    Nuckton, TJ
    Eisner, MD
    Matthay, MA
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : 20 - 27
  • [7] Crystal Ronald G, 2008, Proc Am Thorac Soc, V5, P772, DOI 10.1513/pats.200805-041HR
  • [8] MEDICAL PROGRESS Airway Mucus Function and Dysfunction
    Fahy, John V.
    Dickey, Burton F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23) : 2233 - 2247
  • [9] Necrosis, a well-orchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response
    Festjens, Nele
    Vanden Berghe, Tom
    Vandenabeele, Peter
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2006, 1757 (9-10): : 1371 - 1387
  • [10] The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma
    Gadducci, A
    Cosio, S
    Fanucchi, A
    Negri, S
    Cristofani, R
    Genazzani, AR
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 93 (01) : 131 - 136